# Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury

> **NCT07625553** · PHASE2 · RECRUITING · sponsor: **River 2 Renal Corp.** · enrollment: 430 (estimated)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** R2R01
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07625553
- **Lead sponsor:** River 2 Renal Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-30
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625553, "Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*